There is a strong HTA and Payers presence at the World EPA Congress , making up 10% of attendees and allowing these stakeholders to play a pivotal role in determining whether new healthcare innovations succeed in the market.
Special Advisor, HTA, Zorginstituut Nederland & Professor for HTA of Pharmaceuticals,
Utrecht University
Director of Health Technology Assessment Department, Co-Chair,
HTA Member State Coordination Group, HTA CQ, AGENAS
Senior Advisor, Unit for HTA Cancer Medicines,
Norwegian Medical Products Agency
Health Economics Advisor, Clinical Trials,
Haukeland University Hospital
Director, Pharmacy and Medicines Area,
Consorci De Salut I Social De Catalunya